SELECTIVE ANTAGONISTS OF EP4 RECEPTOR FOR CANCER TREATMENT Russian patent published in 2015 - IPC A61K31/4178 A61K31/437 A61K31/4184 A61P35/00 

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to chemical and pharmaceutical industry and represents application of compound, selected from group, including 3-[2-(4-{2-ethyl-4,6-dimethyl-1H-imidazo[4,5-c]piridin-1-yl}phenyl)ethyl]-1-[(4-methylebenzene)sulphonyl]urea; 4-((1S)-1-{[5-chloro-2-(4-fluorophenoxy)benzoyl]amino}ethyl)-benzoic acid and 4-[(1S)-1-({[5-chloro-2-(3-fluorophenoxy)piridin-3-yl]carbonyl}amino)ethyl]benzoic acid, or its pharmaceutically acceptable salt for production of medication for production of cancer dimensions, associated with prostaglandin E2 (PGE2) (for instance, gastroenterologic cancer, prostate cancer, lung cancer and breast cancer) in humans or animals.

EFFECT: obtaining pharmaceutically acceptable salt for production of medication for reduction of cancer dimensions.

5 cl, 5 dwg, 9 ex